Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gynecologic Oncology Group
With
National Cancer Institute (NCI)
PRIMARY OBJECTIVES:
I. To validate the clinicopathologic associations and prognostic significance of ATR mutation in endometrioid endometrial cancer cases with defective DNA mismatch repair.
OUTLINE: This is a multicenter study.
DNA extracted from previously collected tumor samples is analyzed to validate the clinicopathologic associations and prognostic significance of ATR mutation.
Age
Any age
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Women who were eligible and evaluable for the GOG-0210 molecular staging protocol in women with endometrial cancer
* Women who were registered during the unrestricted enrollment period (through 9/23/07) will automatically qualify
* Women who were registered during the restricted enrollment period (after 9/23/07) will only be considered if needed
Women who had histologically confirmed endometrioid endometrial adenocarcinoma regardless of stage or grade
Women who have defective DNA mismatch repair and are microsatellite instability positive (MSI+ and MSI-low)
Women who consented to allow their specimens and clinical data to be used for future cancer research
Women who have sufficient high-quality genomic DNA from tumor available for mutation analysis of ATR
Clareo Health | Prognostic Biomarkers in Patients With Endometrial Cancer
